February 13–17, 2021 North American winter storm

Atmos Energy Corporation Reports Earnings for Fiscal 2023; Initiates Fiscal 2024 Guidance; Raises Dividend

Retrieved on: 
Wednesday, November 8, 2023

Atmos Energy Corporation (NYSE: ATO) today reported consolidated results for its fourth fiscal quarter and year ended September 30, 2023.

Key Points: 
  • Atmos Energy Corporation (NYSE: ATO) today reported consolidated results for its fourth fiscal quarter and year ended September 30, 2023.
  • Earnings per diluted share was $6.10 for the year ended September 30, 2023; $0.80 per diluted share for the fourth fiscal quarter.
  • Earnings per diluted share for fiscal 2024 is expected to be in the range of $6.45 to $6.65 per diluted share.
  • The indicated annual dividend for fiscal 2024 is $3.22, which represents an 8.8% increase over fiscal 2023.

Voltus Drives Energy Transition Victory as Missouri Commission Votes Unanimously to Support Consumer Access to Wholesale Power Markets

Retrieved on: 
Monday, October 16, 2023

On October 12, 2023, the Missouri Public Service Commission (MPSC) unanimously ruled to reverse their FERC Order 719 opt-out .

Key Points: 
  • On October 12, 2023, the Missouri Public Service Commission (MPSC) unanimously ruled to reverse their FERC Order 719 opt-out .
  • Missouri’s Public Service Commission opted out of FERC Order 745 in 2010 ( Order Temporarily Prohibiting the Operation of Aggregators of Retail Customers ).
  • In February of 2021, the MPSC invited comments on how the commission should respond to FERC Order 2222.
  • Voltus, Walmart, and other parties participated in workshops and submitted briefs in support of reversing the opt-out.

Basin Water Resources LLC Responds to Saltwater Crisis, Providing Mobile Reverse Osmosis Systems to Plaquemines Parish

Retrieved on: 
Monday, October 2, 2023

NEW ORLEANS, Oct. 2, 2023 /PRNewswire/ -- Basin Water Resources LLC (BWR), a leading provider of innovative water solutions, announces its commitment to addressing the saltwater crisis in Plaquemines Parish.

Key Points: 
  • NEW ORLEANS, Oct. 2, 2023 /PRNewswire/ -- Basin Water Resources LLC (BWR), a leading provider of innovative water solutions, announces its commitment to addressing the saltwater crisis in Plaquemines Parish.
  • In response to the urgent need for freshwater, Basin Water Resources LLC is proud to deploy state-of-the-art mobile reverse osmosis systems capable of producing up to 1 million gallons per day (MGD) of clean, potable water.
  • The saltwater crisis in Plaquemines Parish has posed significant challenges to the local community and its access to safe drinking water.
  • Key highlights of Basin Water Resources LLC's initiative:
    1 Million Gallons per Day Production Capacity: BWR's mobile reverse osmosis systems are equipped to generate up to 1 MGD of fresh water, providing a substantial and immediate supply of clean drinking water to the residents of Plaquemines Parish.

Nachawati Law Group Partners Named Among Best Lawyers in America

Retrieved on: 
Thursday, August 17, 2023

DALLAS, Aug. 17, 2023 /PRNewswire/ -- Two Nachawati Law Group partners have earned placement in the 2024 edition of The Best Lawyers in America, the oldest peer review guide that highlights the leading attorneys in the nation. Firm founder Majed Nachawati and trial lawyer Steven Schulte are each honored for excellence in personal injury litigation on behalf of plaintiffs.

Key Points: 
  • DALLAS, Aug. 17, 2023 /PRNewswire/ -- Two Nachawati Law Group partners have earned placement in the 2024 edition of The Best Lawyers in America, the oldest peer review guide that highlights the leading attorneys in the nation.
  • The recognition by Best Lawyers is just the latest in a long list of accolades for the esteemed trial lawyers.
  • Mr. Nachawati and Mr. Schulte have each earned repeat honors by Texas Super Lawyers as well as D Magazine's annual Best Lawyers in Dallas listings.
  • Nachawati Law Group represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation, and individual victims in complex personal injury litigation.

Atmos Energy Corporation Reports Earnings for Fiscal 2023 Third Quarter; Reaffirms Fiscal 2023 Guidance

Retrieved on: 
Wednesday, August 2, 2023

Atmos Energy Corporation (NYSE: ATO) today reported consolidated results for its third fiscal quarter ended June 30, 2023.

Key Points: 
  • Atmos Energy Corporation (NYSE: ATO) today reported consolidated results for its third fiscal quarter ended June 30, 2023.
  • Earnings per diluted share was $5.33 for the nine months ended June 30, 2023; $0.94 per diluted share for the third fiscal quarter.
  • Consolidated net income was $767.3 million for the nine months ended June 30, 2023; $137.8 million for the third fiscal quarter.
  • Earnings per diluted share for fiscal 2023 is expected to be in the range of $6.00 to $6.10 per diluted share.

Atmos Energy Corporation Reports Earnings for Fiscal 2023 Second Quarter; Tightens Fiscal 2023 Guidance

Retrieved on: 
Wednesday, May 3, 2023

Atmos Energy Corporation (NYSE: ATO) today reported consolidated results for its second fiscal quarter ended March 31, 2023.

Key Points: 
  • Atmos Energy Corporation (NYSE: ATO) today reported consolidated results for its second fiscal quarter ended March 31, 2023.
  • Earnings per diluted share was $4.40 for the six months ended March 31, 2023; $2.48 per diluted share for the second fiscal quarter.
  • Consolidated net income was $629.5 million for the six months ended March 31, 2023; $357.7 million for the second fiscal quarter.
  • Fiscal 2023 earnings guidance was tightened to $6.00 to $6.10 per diluted share from $5.90 to $6.10 per diluted share.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023

This approval enables Cidara to receive a $20.0 million regulatory milestone payment under the terms of our agreement with Melinta Therapeutics,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • This approval enables Cidara to receive a $20.0 million regulatory milestone payment under the terms of our agreement with Melinta Therapeutics,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • In addition, we announced the nomination of our first oncology DFC candidate, CBO-212, and presented preclinical data at the ESMO-TAT conference.
  • We are currently conducting investigational new drug (IND)-enabling activities for CD421, which is an enhanced version of CBO-212.
  • The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $19.5 million.

Spearmint Energy Expands Portfolio with Acquisition of 900 MW of Energy Storage Development Assets in ERCOT Power Market

Retrieved on: 
Tuesday, March 21, 2023

Spearmint Energy (“Spearmint” or the “Company”), a next-generation renewable energy company enabling the clean energy revolution through battery energy storage, today announced that is has acquired a 900 MW portfolio of battery energy storage solutions (“BESS”) assets, collectively known as Nomadic.

Key Points: 
  • Spearmint Energy (“Spearmint” or the “Company”), a next-generation renewable energy company enabling the clean energy revolution through battery energy storage, today announced that is has acquired a 900 MW portfolio of battery energy storage solutions (“BESS”) assets, collectively known as Nomadic.
  • The acquisition significantly expands Spearmint’s BESS portfolio and cements the Company as the one of the largest battery energy storage developers in the state of Texas.
  • Over the next several months, Spearmint’s growing team of industry veterans will complete Nomadic’s remaining development work.
  • “We are proud to add Nomadic to the Spearmint portfolio,” said Andrew Waranch, Founder, President, and Chief Executive Officer of Spearmint.

Texas Coalition for Affordable Power Offers Possible Stability of Electricity Rates for Members

Retrieved on: 
Monday, March 6, 2023

The largest non-profit aggregator of electric power for political subdivisions in Texas has found a way to offer rate stability to its members, resulting in a lower total price for electricity.

Key Points: 
  • The largest non-profit aggregator of electric power for political subdivisions in Texas has found a way to offer rate stability to its members, resulting in a lower total price for electricity.
  • The Texas Coalition for Affordable Power (TCAP) will be obtaining their ancillary services from Broad Reach Power (BRP), the leading utility-scale battery storage platform in the United States.
  • This proves once again that TCAP’s non-profit model enables innovation and creativity, the focus of which is solely on the benefit of its members.
  • For more information about the TCAP, visit www.tcaptx.com
    Broad Reach Power is the leading utility-scale battery storage platform in the United States.

Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model

Retrieved on: 
Wednesday, March 1, 2023

As evidenced by animal efficacy studies, CD388 has the potential to be a long-acting antiviral drug designed to deliver universal prevention of seasonal and pandemic influenza A and B strains.

Key Points: 
  • As evidenced by animal efficacy studies, CD388 has the potential to be a long-acting antiviral drug designed to deliver universal prevention of seasonal and pandemic influenza A and B strains.
  • “This planned interim analysis of our Phase 2a study provides preliminary evidence that CD388 may effectively prevent influenza and supports our belief in the potential of DFCs from our Cloudbreak platform,” said Jeffrey Stein, President and CEO of Cidara Therapeutics.
  • “We are pleased with these interim data and the productive collaboration between the Cidara and Janssen teams and look forward to the availability of final top-line results from this important trial.”
    The interim analysis is based on 56 subjects, with 28 receiving a single dose of CD388 (150 mg) and 28 receiving a placebo.
  • The interim data for the primary outcome measure of Area Under the Viral Load-Time Curve (VL-AUC) and for the infection incidence for CD388 versus placebo are shown below in Table 1.